Effects of Vitamin D Intake on FEV1 and COPD Exacerbation: A Randomized Clinical Trial Study

Abstract

Aim:This study aimed to evaluate the effects of vitamin D intake on COPD exacerbation and FEV1 in the patients with severe and very severe COPD.Methods:This double blind placebo control randomized clinical trial study was done in the Ashayer university hospital in Khorramabad in 2012. Eighty eight patients with severe and very severe COPD were randomly selected from those who recoursed to the internal medicine clinic of Ashayer hospital. They were randomly allocated to case and placebo group. The patients received routine treatment for COPD. Along with the routine treatment, placebo group received 100,000 IU of oral vitamin D per month, for 6 months. Data was analyzed using SPSS computer software, paired t-test, independent t-test, non parametric t-test and Pearson correlation coefficients.Results:In each group, there were 44 patients. After the intervention, there were significant differences in FEV1 and the number of COPD exacerbation between the case and control group patients. Also, after the study, in the case group, FEV1 was increased and the number of COPD exacerbation was decreased significantly.Conclusion:Vitamin D intake decreased COPD exacerbation and improved FEV1 in the patients with severe and very severe COPD. It is suggested that baseline serum vitamin D levels will recorded in similar studies and the effect of vitamin D intake will evaluated regarding the baseline serum vitamin D levels.

The effect of vitamin D on COPD exacerbation: a double blind randomized placebo-controlled parallel clinical trial

“…It was shown that “ Vitamin D intake decreased COPD exacerbation and improved FEV1 in the patients with severe and very severe COPD” [31]. Unfortunately in this study which was carried out in our country the baseline level of vitamin D was not determined.…”

Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials

“…We sought IPD for all four studies and obtained outcome data for 469/472 participants in three studies13–15; data were not obtained for one study (88 participants)16 because the corresponding author advised that the study database had been lost.…”

“…All RCTs contributing data to this meta-analysis were assessed as being at low risk of bias for all aspects considered. The trial by Zendedel et al ,16 which did not contribute data to this meta-analysis, was assessed as being at unclear risk of bias for sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting, and as being at high risk of other bias (validity of primary outcome depended on detailed recall of day-to-day symptoms without use of a diary at 2-month intervals).…”

“…Our findings should therefore be interpreted with caution. We were unable to obtain IPD for one relatively small (n=88) eligible study16; data from this study could not be included in an aggregate data meta-analysis, since summary statistics relating to the rate of exacerbations, the proportion of participants experiencing at least one exacerbation or the time to first exacerbation were not reported. It is questionable, however, whether this study would have contributed useful data to our meta-analysis, since use of antibiotics/systemic corticosteroids was not reported, vitamin D status of participants was not measured and the validity of assessments of exacerbation was assessed as being at high risk of bias.…”

“…Vitamin D deficiency is common in patients with COPD, but consistent associations between circulating concentrations of 25-hydroxyvitamin D (25(OH)D, the major vitamin D metabolite) and risk of COPD exacerbation have not been demonstrated 9–12. Four double-blind placebo-controlled RCTs have been published, investigating effects of vitamin D supplementation on the risk of COPD exacerbation: of these, three reported no effect overall13–15 and one reported a protective effect overall 16. These RCTs have not previously been meta-analysed.…”